Editing Pfizer (section)

===Advances in AI, Gene Therapy, and Breakthrough Treatments=== 

Pfizer has also started initiatives which aim to address healthcare challenges across various regions and therapeutic areas in advancements in artificial intelligence (AI), gene therapy, obesity treatments, and oncology research. In 2023, Pfizer’s affordability and access programs reached 45 million patients in the MERA region, supported by the IUdo app, which was launched in [[Egypt]], [[Qatar]], and [[Lebanon]] to facilitate patient access to care. In 2024, Pfizer focuses on integrating AI and gene therapy in the [[Middle East]], [[Russia]], and [[Africa]] (MERA) region, with its headquarters in [[Dubai]].<ref name="Driving equitable"/> Key initiatives include:
* '''Personalized Healthcare''': Omnichannel strategies are being used to provide tailored healthcare solutions for patients and professionals.<ref>{{cite web |title=Omnichannel Engagement in Pharma: Process and Challenges |url=https://medicaldigitals.com/blogs/pharmaceutical-marketing/omnichannel-engagement-pharma/ |date=24 January 2024|website=Medical Digitals |access-date=6 April 2025}}</ref>
* '''AI-Powered Education Programs:''' AI-driven atrial fibrillation programs localized educational materials into multiple languages, increasing accessibility. 
* '''Rare Disease Research:''' Collaboration with the Abu Dhabi Department of Health to analyze real-world data on Sickle Cell Disease using AI.<ref>{{cite web |title=Department of Health – Abu Dhabi Partners with Pfizer to Advance Research in Sickle Cell Disease and Beyond |url=https://www.doh.gov.ae/en/news/doh-partners-with-pfizer-to-advance-research-in-sickle-cell-disease-and-beyond |website=Department of Health Abu Dhabi|date=4 June 2024|access-date=6 April 2025}}</ref>